Ongoing Clinical Trial Studies
Active
Renal Medicine Associates collaborates with multiple institutions to explore innovative therapeutic options for selected patients, prioritizing excellence in care. With a diverse portfolio of past and present clinical trials, RMA has a proven track record of success in advancing kidney health. We are committed to enhancing access to novel treatment options in New Mexico, empowering patients with a broader range of choices that align with the latest advancements in medicine.
Glomerular & Genetic Disease
Sponsor: Alpine Immune Science
Protocol: AIS-D08
A phase 3, randomized, double-blind, placebo-controlled study of povetacicept in adults with IgAN (Rainier)
Glomerular and Genetic Diseases
Sponsor: Travere Therapeutics
Protocol: TVTX-RE021-204
A multicentered, single-group phase 2, exploratory, open-label study to investigate safety and effect of sparsentan in combination with sodium glucose cotransporter-2 (SGLT2) inhibition in the treatment of adult participants with IDA nephropathy (IGAN)
glomerular and genetic diseases
Sponsor: Vera Therapeutics
Protocol: VT-001-0050
A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in Subjects with IgA Nephropathy (IgAN).
glomerular and genetic diseases
Sponsor: Dimerix Bioscience, Pty Ltd
Protocol: DMX-200--301
A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving an angiotensin II receptor blocker (ARB
glomerular and genetic diseases
Sponsor: Calliditas Therapeutics AB
Protocol: Nef-403
An open-label study to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO® 16 mg once daily treatment in real-world clinical practice
glomerular and genetic disease
Sponsor: Vera Therapeutics
Protocol: VT-001-0051
A Multicenter, Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept
infectious diseases
Sponsor: AstraZeneca AB
Protocol: D7000C00001 SuperNova
A Phase I/III Randomized, Double-blind Study to Evaluate the Safety, Efficacy, and Neutralizing Activity of AZD5156/AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants with Conditions Causing Immune Impairment
Cardiometabolic Medicine
Sponsor: Novo Nordisk
Protocol: NN9838-4942
The cardiovascular safety and efficacy of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with established cardiovascular disease.
Cardiometabolic Medicine
Sponsor: Alnylam Pharmaceuticals
Protocol: ALN-AGT01-007
Description: A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Adult Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications
Closed for Enrollment
End - stage kidney disease
Sponsor: Merck Sharp & Dohme Corporation
Protocol: 007-00
Description: A Randomized Parallel-group, Placebo-controlled, Double-blind, Event-driven, Multi-center Phase 2 Clinical Outcome Trial of Prevention of Arteriovenous Graft Thrombosis and Safety of MK-2060 in Patients With End Stage Renal Disease Receiving Hemodialysis
Closed for Enrollment
Contact Research Team Member